



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Abiraterone (Standard)

Cat. No.:	HY-70013R
CAS No.:	154229-19-3
Molecular Formula:	C ₂₄ H ₃₁ NO
Molecular Weight:	349.51
Target:	Cytochrome P450
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Abiraterone (Standard) is the analytical standard of Abiraterone. This product is intended for research and analytical applications. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17 α -hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC ₅₀ s of 2.5 nM and 15 nM, respectively.
IC ₅₀ & Target	IC ₅₀ :17 α -hydroxylase (2.5 nM), 17,20-lyase (15 nM) ^[6]

REFERENCES

- [1]. Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. *J Clin Oncol.* 2008 Oct 1;26(28):4563-71.
- [2]. Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. *Cancer Res.* 2012 May 1;72(9):2176-82.
- [3]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. *Asian J Androl.* 2014 May-Jun;16(3):387-400.
- [4]. Li R, et al. Abiraterone inhibits 3 β -hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. *Clin Cancer Res.* 2012 Jul 1;18(13):3571-9.
- [5]. Kumar SV, et al. Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. *Biomed Chromatogr.* 2013 Feb;27(2):203-7.
- [6]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. *Asian J Androl.* 2014 May-Jun;16(3):387-400.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA